安徽医科大学学报2018，Vol.53Issue(7)：989-993,5.DOI:10.19405/j.cnki.issn1000-1492.2018.07.001
乳源免疫调节肽通过泛素-蛋白酶体途径抑制卵巢癌耐药性及其机制研究
Immunomodulating peptide inhibits the drug resistance of ovarian cancer cell through the ubiquitin-proteasome pathway
摘要
Abstract
Objective To study the inhibitory effect of immunomodulating peptide ( PGPIPN) on the drug resist-ance and its mechanism in ovarian cancer. Methods The IC50and cell proliferation inhibition rates were detected in human ovarian cancer cell lines ( both sensitive cell line, SKOV3, and drug-resistant cell line, SKOV3-DDP) and primary ovarian cancer cell through the combination of the PGPIPN and cisplatin ( DDP) by MTT method. The PCR and Western blot were used to detect the expressions of genes related to the ubiquitin-proteasome pathway in human ovarian cancer cell lines and primary ovarian cancer cells. Results The experimental results showed that the proliferation inhibition rate in combined drug group was higher than that in the groups treated only with DDP and PGPIPN and the difference was statistically significant ( P＜0. 05) . The results of PCR and Western blot indi-cated that PGPIPN lessened the resistance of ovarian cancer cells to DDP by regulating the expressions of genes re-lated to the ubiquitin-proteasome pathway in human ovarian cancer cell lines and primary ovarian cancer cells. PG-PIPN promoted the expression of SIAH and PSMA1 genes and reduced the expression of β-catenin gene ( P＜0. 05, P＜0. 01) with a dose-dependent manner. Conclusion PGPIPN reduces the resistance of ovarian cancer cells to DDP through the ubiquitin proteasome pathway.关键词
卵巢癌/乳源免疫调节肽/顺铂/泛素-蛋白酶体途径Key words
ovarian cancer/immunomodulating peptide/cisplatin/the ubiquitin-proteasome pathway分类
医药卫生引用本文复制引用
阮昕,汪慎燚,徐恰,席浩,薛绍礼,秦宜德..乳源免疫调节肽通过泛素-蛋白酶体途径抑制卵巢癌耐药性及其机制研究[J].安徽医科大学学报,2018,53(7):989-993,5.基金项目
国家自然科学基金(编号:81472448) （编号:81472448）
安徽省自然科学基金(编号:1508085MH196) （编号:1508085MH196）
